Pfizer vs J&J: Researchers are duking it out for the championship title in nonmetastatic prostate cancer
Both companies posted their abstracts being reviewed at ASCO’s Genitourinary Cancers Symposium Monday evening. And while scientists frown on comparing data from two different studies, you can bet that analysts will be lining up the results side-by-side to see who will come out ahead.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.